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INSIGHTS FROM MODEL SYSTEMS
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The Phenomenon of Cellular Aging
Human aging is a highly complex process, resulting from
a number of small changes that differ from tissue to
tissue. Several major obstacles have interfered with the
study of aging in whole organisms. These include the
genetic heterogeneity between individuals and the dif-
ficulty in distinguishing the consequences of normal ag-
ing from the effects of diseases that occur throughout
life (see Scha¨chter 1998 [in this issue]). For these reasons,
human cells grown in culture offer a simplified and at-
tractive model with which to study cellular processes
involved in aging. More than 30 years ago, Hayflick and
Moorhead reported that diploid fibroblasts undergo a
finite number of cell divisions, after which they stop
proliferating. This phenomenon was equated with nor-
mal cellular aging and was termed “replicative senes-
cence” (Hayflick 1965). Various other cell types have
since been found to undergo replicative senescence, in-
cluding epidermal keratinocytes, smooth-muscle cells,
lens epithelial cells, glial cells, endothelial cells, mela-
nocytes, T lymphocytes (see Effros 1998 [in this issue]),
and adrenocortical cells.
What defines replicative senescence? Cells having
completed a finite number of divisions in culture become
irreversibly growth arrested in the G1 stage of the cell
cycle. A distinctive feature of senescent cells is that they
persist in this state from months to as long as several
years, remaining metabolically active but incapable of
DNA synthesis (Matsumura et al. 1979). This block in
cell-cycle progression in senescent cells is irreversible and
is not associated with programmed cell death. Senescent
cells also undergo morphological changes that include
enlargement and flattening of the cells and an unex-
plained expression of a b-galactosidase activity at pH 6
(Dimri et al. 1995). These criteria are few, in part because
many changes that occur in senescence are also seen in
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the reversible quiescent state that some young cells un-
dergo in the absence of growth factors.
The role of replicative senescence in aging of the or-
ganism remains controversial, but correlative evidence
suggests that it is an in vitro manifestation of an in vivo
phenomenon. First, the replicative capacity of cells cul-
tured from old donors is less than that of young donors,
suggesting that cells keep track of the number of cell
doublings that they have undergone in vivo. Second, the
replicative capacity of cells is roughly proportional to
the maximum life span of the animals from which they
originated. A third line of evidence comes from the study
of diseases, such as Werner syndrome (WS), that mimic
premature aging. Fibroblasts obtained fromWS patients
senesce much earlier than normal age-matched controls
(Norwood et al. 1979). The WS gene (WRN) has re-
cently been cloned and displays homology to some DNA
helicases, although all mutations thus far identified map
outside the helicase region, suggesting other possible
functions for this protein (Yu et al. 1996).
Two predominant models have been suggested to ex-
plain the loss of proliferation in senescence. The first
proposes that cellular aging results from the accumu-
lation of errors that occur, perhaps, as a result of either
impaired DNA repair mechanisms or inadequate free
radical–scavenging abilities. Thus, the cell is seen as pas-
sive in the aging process, although it may be able to
regulate the process by repairing or removing damaged
cellular components. The second model proposes that
cells age according to an intrinsic genetic program and,
hence, suggests that cells are active participants in their
own aging. The majority of the data described below
implicate genetic factors in the activation of cellular
senescence.
Cellular Senescence Is Genetically Dominant:
Somatic Cell–Hybrid Studies
We have exploited clonal cell strains with unusually
long life spans, in order to study the genetics of prolif-
erative potential in somatic cells (Smith and Pereira-
Smith 1996). We found that fusions between young and
old cells yield hybrids with life spans similar to that of
the old parental cells, suggesting that the senescent phe-
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notype is dominant. Moreover, fusion between old cell
populations does not produce hybrids with a life span
greater than that of either parental cell line, providing
further evidence for dominant-negative regulatorymech-
anisms causing senescence. Confirmation of the domi-
nance of the senescent phenotype came from the fusion
of various immortal and normal (mortal) human fibro-
blasts, resulting in hybrids with a limited doubling po-
tential. The same outcome was observed when different
immortal cell lines were fused with highly differentiated
cell types, such as normal human T cells and endothelial
cells (Pereira-Smith et al. 1990). Together, these data
support a genetic basis for cell aging and indicate that
immortal cells arise because of recessive mutations that
allow them to escape senescence. Furthermore, it sug-
gests that senescence is controlled by a common mech-
anism(s) in very different cell types.
Pathways Leading to Senescence:
A Genetic Approach
To establish how many distinct genes play a part in
cellular senescence, a series of immortal human cell lines
were fused with each other. If they possessed the same
recessive defects, the resulting hybridswould be expected
to be immortal, and the cell lines would be assigned to
the same complementation group for indefinite division.
However, fusion of immortal cells with different reces-
sive mutations would result in a limited proliferative
potential, thus corresponding to different complemen-
tation groups. By means of this approach, 140 different
immortal cell lines have been assigned to four comple-
mentation groups for indefinite division, groups desig-
nated “A”–“D” (Smith and Pereira-Smith 1996), indi-
cating that at least four genes are required for the
induction of senescence.
The demonstration of different complementation
groups provided the tools for a more focused analysis
of the genetic pathways of cell aging. One approach was
to identify specific chromosomes encoding senescence-
inducing genes. By definition, these genes should be ca-
pable of complementing the immortal phenotype of cell
lines assigned to the same group, but not of cells of the
other groups. Microcell-mediated chromosome transfer
allowed the introduction of single human chromosomes
into immortal human cell lines assigned to the different
complementation groups (Smith and Pereira-Smith
1996). Three candidate chromosomes were initially
tested because of their prior association to tumor-sup-
pressive mechanisms. Whereas chromosome 11 dem-
onstrated no senescence-inducing effects, chromosomes
1 and 4 reversed the immortal phenotype in comple-
mentation groups C and B cell lines, respectively (Smith
and Pereira-Smith 1996). This effect was group specific
in that either the introduction of human chromosome 4
into cell lines assigned to complementation groups A,
C, or D, or the introduction of chromosome 1 into
groups A, B, or D had no effect on proliferation. Ogata
et al. (1993) reported that human chromosome 7 sup-
pressed proliferation of two human transformed fibro-
blast cell lines, SUSM-1 (complementation group D) and
KMST-6 and followed with a complete analysis of cell
lines assigned to all the groups (Ogata et al. 1995). To-
gether, these results suggested that chromosomes 1, 4,
and 7 encode senescence genes inactivated in cell lines
of complementation groups C, B, and D, respectively. A
chromosome able to complement the group A defect has
not yet been identified by such genetic analysis, although
chromosome 6 has been found to induce senescence in
one cell line assigned to this group (Sandhu et al. 1994).
Other chromosomes, including 2, 3, 10, and X, were
also shown to induce senescence in various cell lines (see
review by Oshimura and Barrett [1997]), but the spec-
ificity of their effects has not been shown. The strength
of using cell lines already assigned to complementation
groups is that it allows one to test whether multiple cell
lines within a group respond to the introduction of a
particular chromosome by losing proliferation but with-
out having any effect on cell lines assigned to the other
groups. This criterion is essential to establish that the
chromosome is complementing a specific genetic lesion
rather than merely suppressing its effects.
Once a chromosome encoding a senescence gene has
been assigned to a complementation group, a smaller
region must be identified that causes the same pheno-
type. This can be achieved in multiple ways. One ap-
proach is to obtain naturally occurring immortal clones
on continuous subculture of microcell hybrids and to
analyze the revertant clones for common deletions of a
chromosomal region. This approach was successful in
the identification of two candidate regions, at 1q25 and
1q41-42, for a senescence gene on chromosome 1 (Karls-
son et al. 1996; Vojta et al. 1996). Alternatively, radi-
ation can be used effectively to generate radiation-hybrid
panels containing different fragments of the tagged chro-
mosome. This step is crucial to increase the resolution
to a few megabases of DNA so that a genomic contig
can be assembled that covers the entire region of interest.
During the past few years, we have focussed our study
on identification of the senescence gene encoded on hu-
man chromosome 4 (see sidebar). Fortunately, a smaller
fragment of the q arm was isolated in a mouse A9 back-
ground (A94), without the need to establish a radia-
tion-hybrid panel. This small chromosomal fragment
was shown to induce a senescent phenotype when trans-
ferred into group B cell lines, reproducing the earlier
results observed with the entire chromosome. This effect
was specific to group B cell lines in that no effect on
proliferation was observed in the cell lines of groups A,
C, and D. A bacterial artificial chromosome (BAC) con-
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Four ways to achieve mortality
Cellular senescence is the terminally nondividing state that all
normal cells enter after a limited number of divisions. Cells that
fail to undergo senescence—that is, immortal cells, such as the
human cell line HeLa—are convenient tools in cell biology.
Virtually all spontaneously arising immortal cell lines are kar-
yotypically abnormal. When these cells are fused with normal
cells that can undergo senescence, the hybrid cells produced
regain normal patterns of growth control, and they eventually
stop dividing. This suggests that immortal cells are defective or
lacking in expression of senescence-related genes and that this
defect is complemented by fusion with the normal cell. As de-
scribed in the main text, we have used a similar somatic-cell
genetic approach to define four “complementation groups,”
corresponding to at least four different genetic defects that lead
to indefinite division. When cell lines from different comple-
mentation groups are fused, the two genomes complement each
other’s defects, allowing the hybrid to senesce after some num-
ber of divisions. All of the immortal human cell lines that we
have tested fall into one or another of these groups. In principle,
each of the four genetic lesions could be complemented not just
by whole-cell fusion but also by introduction of individual chro-
mosomes or even defined genes; this provides a ready strategy
for cloning of senescence genes by complementation.
Senescent cells are defined by their inability to proliferate,which
can be a tedious phenotype to determine, but, generally, they
can be identified at a glance by their morphology. Senescent
cells become large and flat as they exit the cell cycle. Depicted
above are cultures of HeLa cells in the presence or absence of
a rescuing chromosome. The left panel is a phase micrograph
of these immortal cells as they normally grow on tissue-culture
plastic: small and tightly packed, like tiles in a mosaic. The
middle panel shows HeLa cells with an extra copy of chro-
mosome 11, which fails to rescue the defect in these cells, so
they appear and divide as before. However, cells that carry an
extra, wild-type copy of chromosome 4 can exit the cell cycle
and persist for long periods without dividing. The unusualmor-
phology of these senescent cells is seen in the right panel. This
finding was a key step toward the cloning of the senescence
gene that is defective in HeLa cells, because it directed our
attention to chromosome 4. We have now identified this gene,
which we name “MORF4.”
tig was constructed that covered the region of interest,
initially estimated to measure 500–800 kb of DNA (M.
J. Bertram, N. J. Be´rube´, X. Hang-Swanson, Q. Ran, Y.
Ning, unpublished data). By means of this genomicDNA
in standard cDNA selection strategies, five cDNAs were
identified that mapped to the region encoding the se-
nescence gene. The final step consisted of the transfer of
these candidate genes into group B immortal cell lines,
to assess their capacity to induce senescence. This was
observed for one of the genes, which we named
“MORF4” (for mortality factor 4 [M. J. Bertram, N. J.
Be´rube´, X. Hang-Swanson, Q. Ran, Y. Ning, unpub-
lished data]). Further analysis of this gene and its protein
product are underway and should provide insights into
the mechanisms of cellular aging. This analysis also dem-
onstrates the efficacy of a genetic approach for the iden-
tification of senescence genes.
The Tumor-Suppressor Connection
The loss of growth potential observed in senescent
cells is reminiscent of tumor-suppressive mechanisms. In
fact, many well-characterized tumor suppressors—such
as pRb, p53, p21, p16, and, more recently,
p33ING1—have now been linked to the onset of cellular
senescence. Although they may initially exert a protec-
tive effect on cells by limiting their growth potential, the
random loss of these genes that is incurred by old age
may lead to increased proliferation, and, eventually, to
cancer development.
Two of the well-known tumor-suppressor genes, P53
and RB, participate in replicative senescence.Decreasing
or eliminating the activities of either of these gene prod-
ucts generally has minor effects on the proliferation po-
tential of normal human fibroblasts. However, inacti-
vating both simultaneously can cause significant (120%)
increases in the number of population doublings
achieved. Dual inactivation has been accomplished by
expression of SV40 T antigen, by expression of the hu-
man papilloma-virus proteins E6 and E7, and by use of
antisense oligonucleotides to p53 and Rb RNA (re-
viewed in Campisi 1997). In one case, inactivation of
p53 by the introduction of a dominant-negative form of
p53 resulted in an extension of replicative life span, of
∼16 population doublings (Bond et al. 1995). However,
it is not known what other events, in addition to inac-
tivation of p53, might have resulted from the expression
of the dominant-negative p53 molecule.
A plausible role for Rb in cellular senescence can be
inferred from the increased expression of the cyclin de-
pendent kinase (CDK) inhibitors p21 and p16. Hypo-
phosphorylated Rb acts directly and indirectly as a tran-
scriptional repressor. The indirect action of Rb is due,
at least in part, to the sequestration and inactivation of
the transcription factor E2F. Active E2F is necessary for
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the induction of several genes required for the initiation
and maintenance of the S phase; examples include the
genes for dihydrofolate reductase, cyclin A, thymidine
kinase, and DNA polymerase alpha (Campisi 1997).
A role for p53 is less evident. Although p53 activity
has been reported to increase with in vitro aging (Atadja
et al. 1995), the evidence is not consistent with results
from other studies. Although a basal level of p53 appears
to be required for normal replicative senescence, it does
not appear to be responsible for the increase in p21 and
p16 CDK inhibitors, which has been discussed above.
ING1 has been identified as a new potential player in
cell senescence. It was first cloned as a tumor-suppressor
gene encoded on 13p33-34 (Garkavtsev et al. 1997).
Suppression of ING1 mRNA in normal cells induces a
tumorigenic phenotype, whereas its overexpression leads
to a G1 arrest akin to senescence (Garkavtsev et al.
1996). Confirming its role in senescence are the fact that
(a) the protein product p33ING1 increases several fold
as the cells age in culture and (b) expression of antisense
ING1 RNA in presenescent fibroblasts results in exten-
sion of life span (Garkavtsev and Riabowol 1997). It is
not yet clear how all these gene changes interact or con-
tribute to senescence.
The Telomere Hypothesis
Cells undergo a limited number of divisions in culture,
implying the use of a counting mechanism for cell di-
vision. Various data demonstrate that the number of
population doublings, not time in culture, is the basis
of senescence. Several hypotheses might explain this phe-
nomenon, but the most attractive at this time is derived
from the observation that telomeres shorten as the cells
age in culture, because of incomplete replication of chro-
mosome ends at each cell division. Human telomeres
consist of TTAGGG-sequence tandem repeats; it is pro-
posed that cells can sense the length of these hexanu-
cleotide tracts and, hence, can “count” how many di-
visions have occurred (Shay and Wright 1991; Harley
and Villeponteau 1995; Levy et al. 1992). Supporting
this hypothesis is the fact that most somatic cells (except
for germ cells and certain stem cells) lack the enzyme
telomerase, which is responsible for the maintenance of
telomeric repeats, whereas most immortal cells have re-
activated this enzyme (reviewed in Holt et al. 1997). By
the addition of telomeric repeats to chromosomal ends,
telomerase is thought to stabilize the chromosomes and
to prevent chromosomal degradation, fusions, and trans-
locations resulting from excessive telomere shortening
(Greider 1990). A more comprehensive description of
telomerase biochemistry and mode of action has been
described by Morin (1997).
Several possible mechanisms by which shortened tel-
omeres might trigger senescence have been hypothesized.
One possibility is that telomeres bind transcription fac-
tors that are released on loss of telomeric repeats and
that are free to either activate senescence-inducing genes
or inactivate genes necessary for cell-cycle progression.
Another possibility is that telomere shortening somehow
induces DNA damage responses leading to cell-cycle ar-
rest. Alternatively, a gene-silencing mechanism has been
proposed, whereby telomeres maintain the surrounding
chromatin in a heterochromatic structure that disap-
pears on the loss of the telomere. Consequently, genes
in that region become expressed and are able to induce
a senescent phenotype. These possibilities have been dis-
cussed in more detail in a recent review (Campisi 1997).
There are limitations to the telomerase model, because
it does not readily extrapolate to other organisms. For
example, mice have very long telomeres, and telomerase
is present in their somatic cells. Mice lacking an essential
subunit of telomerase are still able to undergo malignant
transformation (Blasco et al. 1997). New data in human
models also cannot easily be reconciled with the telo-
merase hypothesis. Thus, telomerase-negative immortal
human cell lines have been reported (Bryan and Reddel
1997), as have telomerase-positive normal somatic cells
with telomeres that continue to shorten with rounds of
replication. Additionally, telomerase activity in somatic-
cell hybrids does not correlate with their ability to un-
dergo senescence or proliferate, suggesting that telom-
erase expression is not strictly necessary for
immortalization and that its absence is not strictly suf-
ficient for the induction of senescence. However, it re-
cently has been shown that the transfection of the te-
lomerase reverse-transcriptase–subunit gene (hTRT) in
cultured fibroblasts extended their life span, further
strengthening a role for telomerase in human cellular
senescence (Bodnar et al. 1998). At the time of publi-
cation of the study’s results, the number of extra dou-
blings induced by hTRT was ∼30 population doublings,
which is the same as that observed in the inactivation
of Rb and p53. It will be of interest to know both how
many more population doublings these transfected fi-
broblasts will achieve and whether the ploidy of the cells
will remain normal.
Conclusions
The study of in vitro cellular senescence has proved
useful as a model to establish a genetic basis for human
aging and continues to be used to resolve the molecular
details of the gene pathways involved. The implications
that mechanisms of tumor suppression have for cell se-
nescence are becoming obvious and could also explain
the phenomenon of reduced growth potential, which oc-
curs in some tissues and organ systems with age. Ex-
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amples include a decline in immune response with aging,
resulting from a decreased proliferative response of T
cells to antigen, and the reduced proliferation of oste-
oblasts, perhaps leading to osteoporosis. The identifi-
cation of the genes involved in senescence will allow us
to determine whether such changes accompanying hu-
man aging are in fact due to programmed senescence
pathways at the cellular level.
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